Paris: Sanofi and Blueprint Medicines Corporation, a US-based, publicly traded biopharmaceutical company specializing in ...

Sanofi and Blueprint Medicines Corporation have entered into an agreement under which Sanofi plans to acquire the US biopharmaceutical company Blueprint for 9.1 billion dollars.

Sanofi SA (NASDAQ:SNY) on Monday agreed to acquire Blueprint Medicines Corporation (NASDAQ:BPMC). The acquisition includes a ...

Sanofi has agreed to acquire US-based Blueprint Medicines for an equity value of $9.1bn to bolster its immunology pipeline ...

Sanofi to acquire Blueprint Medicines for up to $9.5B to expand its rare immunological disease portfolio, including an FDA-approved treatment.

Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in ...

With the deal, Sanofi gains Blueprint’s portfolio of rare immunological disease treatments, including systemic mastocytosis ...

Hudson has previously said he was looking for M&A deals this year to shore up its already-strong position in immunology, ...

DelveInsight’s Peritoneal Cancer Pipeline report depicts a robust space with 55+ active players working to develop 60+ ...